Dividend Aristocrats: 25+ Years of Consecutive Increases
Dividends are the ultimate proof of earnings quality. You can't fake a cash payment to shareholders.
Stoquity AI Committee1Theme Overview
Dividend Aristocrats have historically outperformed the S&P 500 with lower volatility. The 25-year consecutive increase requirement filters for companies with durable competitive advantages and disciplined capital allocation.
2Why Now?
With interest rates potentially stabilizing, income-oriented equities become relatively more attractive. Companies with pricing power to maintain dividend growth through economic cycles deserve premium valuation.
3Screening Methodology
Screen for S&P 500 Dividend Aristocrats (25+ years consecutive increases), ranked by Stoquity composite quality + income score.
Factors used: Dividend GrowthQualityEarnings StabilityCash FlowDividend Yield
4Top Picks (5 Stocks)
Thesis: 62 consecutive years of dividend increases. Diversified healthcare with pharma, MedTech segments. AAA credit rating — one of two US companies.
Risks: Talc litigation overhang; patent cliffs on key drugs (Stelara); slow growth profile limits upside.
Thesis: 68 consecutive years of dividend increases. Portfolio of 20+ billion-dollar brands with global pricing power. Organic sales growth consistently above market.
Risks: Premium valuation vs staples peers; emerging market currency headwinds; private label competition in inflationary periods.
Thesis: 62 years of dividend increases. Asset-light franchise model generates 30%+ operating margins. Expanding into energy drinks, water, and functional beverages.
Risks: Low single-digit revenue growth ceiling; sugar regulation risk; currency translation from 80%+ international revenue.
Thesis: 65+ years of dividend increases. Post-healthcare spinoff (Solventum), refocused on industrial innovation. Trading at historical P/E discount.
Risks: Ongoing PFAS litigation costs; restructuring execution risk; organic growth stagnation in core markets.
Thesis: 52 consecutive dividend increases. Leader in continuous glucose monitoring (FreeStyle Libre) with $6B+ annual revenue. Diversified across diagnostics, nutrition, devices.
Risks: CGM competition from Dexcom; post-COVID diagnostics revenue decline; baby formula segment volatility.
View compact comparison table
| Symbol | Name | Sector | Score | Market Cap |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | Healthcare | 88 | $380B |
| PG | Procter & Gamble | Consumer Staples | 87 | $390B |
| KO | Coca-Cola Company | Consumer Staples | 85 | $310B |
| MMM | 3M Company | Industrials | 78 | $75B |
| ABT | Abbott Laboratories | Healthcare | 86 | $210B |
5Theme Risks
Dividend Aristocrats can become value traps if the business deteriorates while management prioritizes the dividend streak. High payout ratios in declining businesses signal risk, not safety.
Dividend aristocrats (25+ years of consecutive increases) have outperformed the S&P 500 with lower volatility over every 20-year period since 1990.
Screen stocks yourself
Use the same 24-factor scoring model that powers Stoquity portfolios.
Try the AI Screener →